FDA Advisory Committees Exist to Prevent Exactly What Happened with Aducanumab
Problem Definition
The FDA's advisory committee process is the primary mechanism by which independent scientific expertise informs drug approval decisions. When the FDA approves a drug that its own advisory committee voted 10-0-1 against, following documented irregular contact with the manufacturer during the review period, the advisory committee process has failed its stated purpose.
The aducanumab case is not an isolated regulatory error — it is a documented failure mode of a process that lacks binding authority, transparency requirements for industry-FDA contact, and accountability mechanisms when the FDA overrides committee recommendations. Three committee members resigned in protest.
The OIG found the FDA-Biogen interactions 'atypical' and inconsistent with stated policy. Medicare subsequently restricted the drug to clinical trials, functionally reversing the approval's clinical impact. The approval cost no one at the FDA their job. The process that produced it remains unchanged.
Root Causes
FDA advisory committee recommendations are non-binding — the agency can and does override them without providing evidence-specific justification for the departure
Pre-approval contact between FDA review staff and manufacturers is governed by internal policy rather than statute, creating ambiguity about what constitutes inappropriate influence
Accelerated approval's surrogate endpoint standard ('reasonably likely to predict clinical benefit') is a judgment call with insufficient procedural constraints on how that judgment is made